Form 4 for IBRX ImmunityBio, Inc.
Accepted 2023-09-06 00:00:00 ET · period of report 2023-09-01 · accession 0001326110-23-000115 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-06 | 2023-09-01 | IBRX | Sachs David C. | CFO | M - OptEx | $0.00 | +70.7K | 122.0K | +138% | $0 |
| D | 2023-09-06 | 2023-09-01 | IBRX | Sachs David C. | CFO | M - OptEx | $0.00 | -70.7K | 70.7K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-01 | M | A | 70,744 | $0.00 | 122,042 | D | — | — | |
| 2 | Derivative | Restricted Stock Units | 2023-09-01 | M | D | 70,744 | $0.00 | 70,745 | D | — · — to — | 70,744 Common Stock | (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. (F2) Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the shares subject to the RSU award vested on September 1, 2023 and 70,745 of the shares shall vest on January 31, 2024. |